Using a nationwide dataset of private insurance claims, researchers identified patients aged 18–64 years who were enrolled from 2012–2014. The main outcomes included rates of short-term use of oral corticosteroids (defined as <30 days duration), rates of adverse events in corticosteroid users vs. non-users, and the rate ratios for adverse events within 30 day vs. 31–90 day risk periods after treatment initiation. Related Articles
Dexamethasone is given systemically to decrease inflammatory and immune responses. It is used in high doses in emergencies for anaphylactic reactions, spinal cord trauma or shock. It is used in lower doses to treat allergic reactions such as Chronic Obstructive Pulmonary Disease (COPD), hives, itching, inflammatory diseases including arthritis and to manage and treat immune mediated hemolytic anemia and thrombocytopenia. It sometimes is used systemically as a "performance-enhancing” drug because corticosteroids decrease inflammation, possibly enhance glucose metabolism (there is some debate about this) and may have some mood elevating properties. Other corticosteroids are preferred for intra articular use.